BACKGROUND: There are differences in outcomes in blacks compared with whites with lymph node-negative (pN0) colorectal cancer. Recurrence in pN0 patients suggests the presence of occult metastases undetected by conventional approaches. This study explores the association of racial differences in outcomes with occult tumor burden in regional lymph nodes. METHODS: Lymph nodes (range, 2-159) from 282 prospectively enrolled pN0 colorectal cancer patients followed for a median of 24 months (range, 2-63 months) were subjected to molecular analysis. Occult tumor burden was estimated by quantifying the expression of GUCY2C, a biomarker for metastatic colorectal cancer cells. Risk categories defined using occult tumor burden was the primary outcome measure. Association of prognostic variables and risk were defined by multivariate polytomous logistic regression. RESULTS: Occult tumor burden stratified this cohort of 259 whites and 23 blacks into categories with low (60%; recurrence rate [RR] = 2.3%; 95% confidence interval [CI], 0.1%-4.5%), intermediate (31%; RR = 33.3%; 95% CI, 23.7%-44.1%), and high (9%; RR = 68.0%; 95% CI, 46.5%-85.1%; P < .001) risk. Blacks compared with whites exhibited 4-fold greater occult metastases in individual lymph nodes (P < .001). Multivariate analysis revealed that race (P = .02), T stage (P = .02), and number of lymph nodes collected (P = .003) were independent prognostic markers of risk category. Blacks compared with whites were more likely to harbor levels of occult tumor burden, associated with the highest recurrence risk (adjusted odds ratio = 5.08; 95% CI, 1.69-21.39; P = .007). CONCLUSIONS: Racial disparities in stage-specific outcomes in colorectal cancer are associated with differences in occult tumor burden in regional lymph nodes.
BACKGROUND: There are differences in outcomes in blacks compared with whites with lymph node-negative (pN0) colorectal cancer. Recurrence in pN0 patients suggests the presence of occult metastases undetected by conventional approaches. This study explores the association of racial differences in outcomes with occult tumor burden in regional lymph nodes. METHODS: Lymph nodes (range, 2-159) from 282 prospectively enrolled pN0 colorectal cancerpatients followed for a median of 24 months (range, 2-63 months) were subjected to molecular analysis. Occult tumor burden was estimated by quantifying the expression of GUCY2C, a biomarker for metastatic colorectal cancer cells. Risk categories defined using occult tumor burden was the primary outcome measure. Association of prognostic variables and risk were defined by multivariate polytomous logistic regression. RESULTS:Occult tumor burden stratified this cohort of 259 whites and 23 blacks into categories with low (60%; recurrence rate [RR] = 2.3%; 95% confidence interval [CI], 0.1%-4.5%), intermediate (31%; RR = 33.3%; 95% CI, 23.7%-44.1%), and high (9%; RR = 68.0%; 95% CI, 46.5%-85.1%; P < .001) risk. Blacks compared with whites exhibited 4-fold greater occult metastases in individual lymph nodes (P < .001). Multivariate analysis revealed that race (P = .02), T stage (P = .02), and number of lymph nodes collected (P = .003) were independent prognostic markers of risk category. Blacks compared with whites were more likely to harbor levels of occult tumor burden, associated with the highest recurrence risk (adjusted odds ratio = 5.08; 95% CI, 1.69-21.39; P = .007). CONCLUSIONS: Racial disparities in stage-specific outcomes in colorectal cancer are associated with differences in occult tumor burden in regional lymph nodes.
Authors: Dominik Alexander; Nirag Jhala; Chakrapani Chatla; Jon Steinhauer; Ellen Funkhouser; Christopher S Coffey; William E Grizzle; Upender Manne Journal: Cancer Date: 2005-05-15 Impact factor: 6.860
Authors: V W Chen; C M Fenoglio-Preiser; X C Wu; R J Coates; P Reynolds; D L Wickerham; P Andrews; C Hunter; G Stemmermann; J S Jackson; B K Edwards Journal: Cancer Epidemiol Biomarkers Prev Date: 1997-12 Impact factor: 4.254
Authors: Daniel J Sargent; Murray B Resnick; Michael O Meyers; Atoussa Goldar-Najafi; Thomas Clancy; Sharlene Gill; Gary O Siemons; Qian Shi; Brian M Bot; Tsung-Teh Wu; Guillaume Beaudry; Jean-François Haince; Yves Fradet Journal: Ann Surg Oncol Date: 2011-05-01 Impact factor: 5.344
Authors: Ruth Birbe; Juan P Palazzo; Rhonda Walters; David Weinberg; Stephanie Schulz; Scott A Waldman Journal: Hum Pathol Date: 2005-02 Impact factor: 3.466
Authors: G J Liefers; A M Cleton-Jansen; C J van de Velde; J Hermans; J H van Krieken; C J Cornelisse; R A Tollenaar Journal: N Engl J Med Date: 1998-07-23 Impact factor: 91.245
Authors: Itzhak Avital; Russell C Langan; Thomas A Summers; Scott R Steele; Scott A Waldman; Vadim Backman; Judy Yee; Aviram Nissan; Patrick Young; Craig Womeldorph; Paul Mancusco; Renee Mueller; Khristian Noto; Warren Grundfest; Anton J Bilchik; Mladjan Protic; Martin Daumer; John Eberhardt; Yan Gao Man; Björn Ldm Brücher; Alexander Stojadinovic Journal: J Cancer Date: 2013-03-01 Impact factor: 4.207